These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions. Kumar S; Singh SK; Wang X; Rup B; Gill D Pharm Res; 2011 May; 28(5):949-61. PubMed ID: 21437790 [TBL] [Abstract][Full Text] [Related]
12. Deimmunization of protein therapeutics - Recent advances in experimental and computational epitope prediction and deletion. Zinsli LV; Stierlin N; Loessner MJ; Schmelcher M Comput Struct Biotechnol J; 2021; 19():315-329. PubMed ID: 33425259 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic protein deimmunization by T-cell epitope removal: antigen-specific immune responses in vitro and in vivo. Asgari S; Ebrahim-Habibi A; Mahdavi M; Choopani M; Mirzahoseini H APMIS; 2017 Jun; 125(6):544-552. PubMed ID: 28418077 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Cantor JR; Yoo TH; Dixit A; Iverson BL; Forsthuber TG; Georgiou G Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1272-7. PubMed ID: 21209329 [TBL] [Abstract][Full Text] [Related]
15. Removing T-cell epitopes with computational protein design. King C; Garza EN; Mazor R; Linehan JL; Pastan I; Pepper M; Baker D Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8577-82. PubMed ID: 24843166 [TBL] [Abstract][Full Text] [Related]
16. Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions. Parker AS; Griswold KE; Bailey-Kellogg C J Bioinform Comput Biol; 2011 Apr; 9(2):207-29. PubMed ID: 21523929 [TBL] [Abstract][Full Text] [Related]
17. Implications of available design space for identification of non-immunogenic protein therapeutics. Lee SC Biomed Microdevices; 2010 Apr; 12(2):283-6. PubMed ID: 20012559 [TBL] [Abstract][Full Text] [Related]
18. Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity. Dhanda SK; Grifoni A; Pham J; Vaughan K; Sidney J; Peters B; Sette A Immunology; 2018 Jan; 153(1):118-132. PubMed ID: 28833085 [TBL] [Abstract][Full Text] [Related]
19. Introducing of an integrated artificial neural network and Chou's pseudo amino acid composition approach for computational epitope-mapping of Crimean-Congo haemorrhagic fever virus antigens. Nosrati M; Mohabatkar H; Behbahani M Int Immunopharmacol; 2020 Jan; 78():106020. PubMed ID: 31776090 [TBL] [Abstract][Full Text] [Related]
20. Landscape and selection of vaccine epitopes in SARS-CoV-2. Smith CC; Olsen KS; Gentry KM; Sambade M; Beck W; Garness J; Entwistle S; Willis C; Vensko S; Woods A; Fini M; Carpenter B; Routh E; Kodysh J; O'Donnell T; Haber C; Heiss K; Stadler V; Garrison E; Sandor AM; Ting JPY; Weiss J; Krajewski K; Grant OC; Woods RJ; Heise M; Vincent BG; Rubinsteyn A Genome Med; 2021 Jun; 13(1):101. PubMed ID: 34127050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]